(Q48765862)

15 February 2018

title

Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls. (English)

1 reference

15 February 2018

0 references

0 references

Hahne S

1

1 reference

15 February 2018

Nordstedt C

series ordinal

2

1 reference

15 February 2018

Ahlin A

series ordinal

3

1 reference

15 February 2018

Nybäck H

series ordinal

4

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 March 1997

1 reference

15 February 2018

published in

Neuroscience Letters

1 reference

15 February 2018

volume

224

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

99-102

1 reference

15 February 2018

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

The Global Deterioration Scale for assessment of primary degenerative dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

The molecular pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Presenilins and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Apolipoprotein E genotyping by one-stage PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

Is Alzheimer's disease an apolipoprotein E amyloidosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2897%2913477-2

7 January 2021

10.1016/S0304-3940(97)13477-2

Identifiers

DOI

1 reference

15 February 2018

PubMed ID

9086466

1 reference

15 February 2018